Teva Pharmaceutical Industries Limited TEVA
TASE · Israel · Health Technology
ILA 12,160.00-150.00 (-1.22%)
Market closed· · ILA · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · ILA · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
The fund cited Teva’s share appreciation, branded-drug growth and improved margins as it explained its second-quarter exit.
CEO Richard Francis says Teva is on track for cost savings and sees a pipeline of new medicines supporting growth beyond 2026.
Branded medicines and biosimilars are reshaping Teva’s revenue mix as management targets faster growth and a sturdier balance sheet.
INCHEON, Korea & TEL AVIV, Israel, October 01, 2026--Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referencing Ilaris®2 (canakinumab).
Serge Rogasik TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness TAPI Steroid manufacturing TAPI Steroid manufacturing TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global business that combines a broad API portfolio, deep scientific and technical capabilities, and an extensive global operations n
UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.
Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.
Built on substance, not hype, Teva's mega rally is just getting started.
DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.FDA approval of DEGEVMA marks another milestone in Teva’s Pivot to Growth strategy, demonstrating our ability to bring high-quality, more affordable treatment opt
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financial results on Tuesday, November 3, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your person
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “Investors” page on its website. Q3 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of third quarter 2026 results, which are expected to be released on Tuesday, November 3, 2026, at 7:00 a.m. ET, followed
Teva Pharmaceutical (TEVA) is entering a strong growth phase despite near-term concerns around Auste
Teva Pharmaceutical Industries (NYSE:TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard Francis said at the BofA Global Healthcare Conference. Francis said the company achieved the miles
Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company with a growing innovative medicines portfolio, while maintaining and expanding its generics operat
Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after its U.S. affiliate shared fresh Phase 3 SOLARIS data on investigational olanzapine LAI TEV-749 for adults with schizophrenia. The SOLARIS update follows a strong run for Teva Pharmaceutical Industries, with the share price at US$38.98 and a 7-day share price return of 5.35% building on an 18.7% year-to-date share price gain. A 3-year total shareholder return of about 2.8x and a 5-year total shareholder return of about 3.4x...
MONTPELLIER, France, September 21, 2026--Medincell's partner Teva presented new data on investigational Olanzapine long-acting injectable (LAI) and UZEDY®, two treatments utilizing Medincell's proprietary BEPO® technology, licensed to Teva as SteadyTeq™. The findings were presented at Psych Congress 2026, held from September 15 to 19 in New Orleans, Louisiana.
New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tardive dyskinesia (TD) in patients aged ≥55 yearsAcross all four patient profiles, AUSTEDO® (deutetrabenazine) was most closely related to the attributes most valued by healthcare providersThese findings from Teva detail specific healthcare provider preferences around tolerability and efficacy, while
New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I)The new real-world data also show that UZEDY decreased emergency room visits and hospitalizations, lowering overall healthcare resource utilization and delivering over $1,000 per patient per month in direct cost savingsThe breadth of clinical evidence presented highlights Teva’s ongoing commitment to evaluating how thera
In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of participants receiving TEV-'749 for ≥ 6 months met criteria for remission Treatment switch analyses provide clinical insights into maintaining established therapeutic ranges of olanzapine when initiating TEV-'749 from existing regimens Ahead of the Q4 FDA anticipated approval decision, the growing bod
Options traders are targeting FPS, TEVA, and AFL
Long-acting injectables (LAIs) offer an opportunity to improve adherence and potential outcomes for patients with schizophreniaLongActingImpact.com is a new resource center designed to support clinicians in having informed treatment conversations with those living with schizophreniaAs a leader in neuroscience, Teva is committed to supporting clinicians by providing evidence-based resources which could help improve schizophrenia care PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 16, 2026 (GLOBE N
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.